Inhibitors of TSSK4 function by targeting various signaling pathways and kinase activities that are essential for the protein's role in cellular processes. These compounds interfere with kinase activity, a characteristic function of TSSK4, by inhibiting protein kinases that share similar substrate preferences or are involved in the same signaling cascades. For instance, some of these inhibitors are potent antagonists of protein kinase C and protein kinase A, both of which are known to phosphorylate serine and threonine residues, a key action of TSSK4. Thus, by suppressing these kinases, the phosphorylation status and subsequent signaling events that TSSK4 might regulate are attenuated. Furthermore, the intervention in the PI3K and MAPK pathways, which may indirectly involve TSSK4, leads to a decrease in the functional activity of this kinase. The blockade of these pathways by specific inhibitors results in an indirect dampening of TSSK4's activity, as they prevent the activation of downstream effectors that could be potential substrates or partners of TSSK4.
Moreover, inhibitors that interfere with the JNK, ERK, and p38 MAP kinase pathways also contribute to the inhibition of TSSK4. These inhibitors work by preventing the phosphorylation cascade that TSSK4 may be a part of, thereby reducing its ability to contribute to cellular signaling. The use of mTOR inhibitors further exemplifies the indirect approach to inhibiting TSSK4, as mTOR signaling is crucial for cell growth and proliferation, processes in which TSSK4 could play a role. Inhibitors of this pathway impose a restraint on TSSK4's potential involvement in these biological events. Additionally, the inhibition of receptor tyrosine kinases, which are upstream of various signaling pathways, can also lead to a reduction in TSSK4 activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
This alkaloid inhibits protein kinases by mimicking ATP-binding sites, leading to reduced phosphorylation activity of TSSK 4. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $92.00 $182.00 | 71 | |
A potent inhibitor of protein kinase A (PKA) that can disrupt downstream signaling, thus indirectly inhibiting TSSK 4's serine/threonine kinase activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
A selective inhibitor of protein kinase C (PKC) that, by decreasing PKC activity, can down-regulate pathways that might otherwise phosphorylate substrates of TSSK 4. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which by inhibiting JNK can suppress the phosphorylation of targets potentially overlapping with those of TSSK 4. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphoinositide 3-kinases (PI3K) inhibitor that, by disrupting PI3K-Akt pathway, can indirectly affect the kinase activity of TSSK 4 involved in similar signaling cascades. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
This MEK inhibitor disrupts the MAPK/ERK pathway, which can indirectly impact TSSK 4's activity due to the kinase's potential role in ERK-mediated signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
By inhibiting PI3K, this compound may indirectly reduce the activity of TSSK 4, which is involved in downstream signaling pathways regulated by PI3K. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that could indirectly inhibit TSSK 4 by disrupting signaling pathways where p38 MAPK and TSSK 4 might have intersecting roles. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
A dual tyrosine kinase inhibitor targeting EGFR and HER2 that might indirectly reduce TSSK 4 activity by altering signaling networks where TSSK 4 is a downstream effector. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A RAF kinase inhibitor that may indirectly reduce TSSK 4 activity by modulating the MAPK/ERK pathway, affecting signaling cascades involving TSSK 4. | ||||||